Clinical Trials Search
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Primary: To determine the MTD or RP2D of CB-839 HCl in combination with carfilzomib and dexamethasone. Secondary: Evaluate the safety and tolerability of CB-839 HCl in combination with carfilzomib and dexamethasone. To determine the overall response rate (ORR) associated with the combination of CB-839 HCl with carfilzomib and dexamethasone. Although the clinical benefit of this drug combination has not yet been established, the intent of offering this treatment is to provide a possible therapeutic benefit and thus, the patient will be carefully monitored for tumor response and symptom relief in addition to safety and tolerability.